Browse a selection of key resources and publications about our pipeline.

CLN-978: Mechanism of Action: T Cell Engagers

Mechanism of Action: T Cell Engagers

Modulating the Immune System: An Intricate Balancing Act

Advances in Autoimmune Diseases: A Conversation with Dr. Ricardo Grieshaber-Bouyer

CLN-978, A CD19-Directed T-Cell Engager (TCE), Leads to Rapid and Deep B-Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases (2024 ACR)

Safety and Antitumor Activity of Zipalertinib in NSCLC Patients With EGFR Exon 20 Insertion Mutations Who Received Prior Amivantamab (2024 ESMO)

CD19-Directed T Cell-Engaging Antibodies for the Treatment of Autoimmune Disease (2024 JEM)

CLN-978, a Novel CD19/CD3/HSA-Specific T Cell Engager With Extended Serum Half-Life, Is Effective Against Target Cells Expressing Very Low Levels of CD19 (2023 SITC)

CLN-978, a Novel Half-Life Extended CD19/CD3/HSA-Specific T Cell-Engaging Antibody Construct With Potent Activity Against B-Cell Malignancies With Low CD19 Expression (2023 JITC)

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions (2023 JCO)